Stephen Saad, Group Chief Executive, Aspen
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Address: 15e Riley Road
Bedfordview 2008 ,South Africa
Tel: +27 11 087 0000
iNova Pharmaceuticals develops and markets a range of over-the-counter and prescription medicines to Australasia, Asia-Pacific, South Africa, the Americas and other international markets.
iNova has a broad range of prescription medicines and consumer healthcare products in several therapy areas including pain management, weight management, allergy, sexual health, dermatology, cardiology and respiratory health.
Among the wide variety of products iNova offers in our commitment to improving people’s health and well being are Australian made and owned market leading brands Difflam™, Duro-Tuss™, Hiprex™, Metsal™ and Cal-Sup™. We are also proud to make available to patients and consumers Azep®, Eyezep®, ZepAllergy™ and Rinar™.
Our broad product range, available in pharmacies only, comes from a heritage of many years of innovation and, more recently, in-licensed products. Strict quality assurance and control procedures help to ensure iNova produces and markets brands meeting the most rigorous quality standards. Our products are prescribed by specialist health care providers and general practitioners across the Region and supported by pharmacy recommendation.
The availability of our marketed products and information we lawfully can provide varies among countries. This website contains information on products which is targeted to a wide range of audiences and may contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
The line between research based pharmaceutical companies and generic companies is today less and less relevant, as we have seen in the past few years generic companies climb up the…
Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic…
Your professional career went back and forth between creating your own business and running a smaller and very dynamic structure and managing over a thousand of employees for multinational organizations.…
You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting…
Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes…
An emerging country with a dynamic market, South Africa is widely seen as the gateway to Africa. From major multinational pharmaceutical corporations to burgeoning local generic companies, a wide…
We interviewed Graham Somerville in 2004, the year when IHD, formerly jointly owned by 11 major pharmaceutical companies, was acquired by UTi. We are interviewing you today at the head…
Dr Pillay, South Africa recently became a member of BRICS. With this distinction, we need to improve our healthcare outcomes relative to other BRICS countries. All countries have challenges with…
The South African affiliate was established in June 2003. Could you come back on the main milestones in the company’s development from 2003 onwards? Yamanouchi as an entity was an…
Since we that came to South Africa in 2005 and interviewed you, what have been the main changes both in the market place, and within Sanofi as an organization? The…
In 2005, when Focus Reports interviewed you, you were more towards the start up phase of Pharma Dynamics; and you have significantly grown in the market since then. What new…
Mr. Ehsan, you are the General Manager of IMS Africa since January 2010. What is the strategic importance of South Africa for IMS Global and for your personal country portfolio?…
See our Cookie Privacy Policy Here
